The city of Boston, Massachusetts, currently has 147 active clinical trials seeking participants for Breast Cancer research studies.
Taking AIM at Breast Cancer
Recruiting
The purpose of this research is to determine whether a 16-week exercise program for individuals with breast cancer and have completed treatment (i.e., surgery, chemotherapy, or radiation) for breast cancer will decrease inflammation in fat tissue.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
Recruiting
The purpose of this research is to determine whether a 16-week high intensity interval training (HIIT) exercise program will improve brain health among women undergoing chemotherapy and also improve cardiovascular (heart) function. The names of the study interventions involved in this study are/is: High-Intensity Interval Training (HIIT)
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/19/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Breast Cancer, Chemotherapy Effect, Exercise Therapy, Cognitive Change
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Recruiting
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
Gender:
All
Ages:
70 years and above
Trial Updated:
01/18/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Study to Evaluate CCS1477 in Advanced Tumours
Recruiting
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Metastatic Castration-Resistant Prostate Cancer, Advanced Solid Tumors, Metastatic Breast Cancer, Non-small Cell Lung Cancer
Losartan in Prevention of Radiation-Induced Heart Failure
Recruiting
This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer. The interventions involved in this study are: Losartan Radiation Therapy (standard of care)
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer, Myocardial Fibrosis, Radiation-Induced Fibrosis
Ultrahypofractionation and Normal Tissue Toxicity
Recruiting
This research is being done to see if proton beam radiation therapy (PBT) results in fewer changes to a participant's heart measured with MRI-imaging than conventional or "photon" radiation therapy (XRT) for participants with non-metastatic left sided breast cancer. The names of the two study groups in this research study are: Proton Radiation Therapy (PBT) Conventional or "Photon" Radiation Therapy (XRT)
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer, Breast Cancer Female, Breast Cancer Stage II, Breast Cancer Stage III, Myocardial Fibrosis
Phase 1b Combo w/ Ribociclib and Alpelisib
Recruiting
This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer, HER2-negative Breast Cancer
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Recruiting
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is impo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
Recruiting
The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment and alpelisib may prevent the patient from getting a rash.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/21/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer
Refining Local-Regional Therapy for IBC
Recruiting
This Feasibility study is trying to determine: If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients with inflammatory breast cancer. The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for lymphoscintigraphy. The incidence of lymphedema (arm swelling which occurs after lymph node surgery) in women with inflammatory brea... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/18/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Inflammatory Breast Cancer, Sentinel Lymph Node
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Recruiting
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/13/2023
Locations: Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts
Conditions: Metastatic Breast Cancer